Cantargia AB (STO:CANTA), a biotechnology company that develops antibody-based treatments for life-threatening diseases, announced on Wednesday the submission of a request for a pre-IND meeting with the US Food and Drug Administration (FDA).
Reportedly, the purpose of the meeting is to discuss the current documentation on the antibody CAN04 and a proposed new phase I clinical combination study with CAN04 and an immune checkpoint inhibitor under a US IND.
According to the company, the plan is to conduct this trial at clinical centres in the United States.
Cantargia develops antibody-based pharmaceuticals against the interleukin 1 receptor accessory protein (IL1RAP). The antibody CAN04 binds IL1RAP with high affinity and functions through both ADCC and blockade of interleukin 1 signalling.
Currently, CAN04 is being investigated in a European open label three-armed phase I/IIa clinical trial, CANFOUR, examining monotherapy as well as combination with two different standard chemotherapy regimes in patients with non-small cell lung cancer or pancreatic cancer.
This new proposed clinical trial will investigate CAN04 in combination with an immune checkpoint inhibitor. The design has been developed in collaboration with experts in the field. The purpose of the trial is primarily to investigate safety of the combination therapy in a few selected IL1RAP expressing cancer forms which are currently being treated with immune checkpoint inhibitors. Besides safety, biomarkers and efficacy will also be studied.
A more detailed design will be presented after potential input from the FDA, the company added.
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes
Merck finalises acquisition of Harpoon Therapeutics Inc
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
Nuvalent's NVL-520 receives FDA breakthrough therapy designation
Dassault Systèmes enhances patient care with virtual twin experience at Paris hospital
Pulmonx initiates CONVERT II trial for AeriSeal System in COPD treatment
Priority Review of Dupixent underway by FDA for COPD treatment
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
AstraZeneca reports positive resultsfor Tagrisso in Stage III lung cancer trial
AstraZeneca announces US acceptance of BLA for datopotamab deruxtecan to treat lung cancer
Erasca agrees clinical trial deal with Novartis to study naporafenib in combination with trametinib
FDA accepts Bristol Myers Squibb's Augtyro application for Priority Review